{"id":"loteprednol-tobramycin","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation or discomfort"},{"rate":null,"effect":"Transient blurred vision"},{"rate":null,"effect":"Allergic conjunctivitis"},{"rate":null,"effect":"Secondary infection (if steroid-induced immunosuppression)"}]},"_chembl":{"chemblId":"CHEMBL1200865","moleculeType":"Small molecule","molecularWeight":"466.96"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Loteprednol is a corticosteroid that suppresses inflammatory responses in the eye by binding glucocorticoid receptors and reducing production of inflammatory mediators. Tobramycin is an aminoglycoside antibiotic that inhibits bacterial 30S ribosomal subunit function, preventing protein synthesis and causing bactericidal activity. The combination addresses both inflammatory and infectious components of ocular disease.","oneSentence":"Loteprednol reduces ocular inflammation via glucocorticoid receptor activation, while tobramycin provides broad-spectrum bacterial coverage by inhibiting bacterial protein synthesis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:53:10.811Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Steroid-responsive inflammatory ocular conditions with bacterial infection or risk thereof"},{"name":"Post-operative ocular inflammation and infection"}]},"trialDetails":[{"nctId":"NCT05353101","phase":"PHASE1","title":"Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis Trial","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2020-07-01","conditions":"Vernal Keratoconjunctivitis, Cyclosporine 0.05% Eye Drops","enrollment":48},{"nctId":"NCT03464435","phase":"PHASE4","title":"A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis","status":"COMPLETED","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2016-11-01","conditions":"Vernal Keratoconjunctivitis","enrollment":20},{"nctId":"NCT01456780","phase":"PHASE4","title":"Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis","status":"COMPLETED","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2011-08","conditions":"Meibomian Gland Dysfunction, Posterior Blepharitis","enrollment":60},{"nctId":"NCT00705159","phase":"PHASE4","title":"Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2008-06","conditions":"Conjunctivitis","enrollment":137},{"nctId":"NCT01028027","phase":"PHASE3","title":"Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2009-10","conditions":"Conjunctivitis, Keratitis, Blepharitis","enrollment":357},{"nctId":"NCT00447577","phase":"PHASE4","title":"Zylet vs TobraDex in Blepharokeratoconjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2007-01","conditions":"Blepharokeratoconjunctivitis","enrollment":276},{"nctId":"NCT00532961","phase":"PHASE4","title":"Ocular Tolerance and Intraocular Pressure (IOP) Effects of Zylet Versus Tobradex","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2005-02","conditions":"Inflammation","enrollment":310},{"nctId":"NCT00420628","phase":"PHASE4","title":"Pediatric Zylet Safety and Efficacy Study","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2006-11","conditions":"Chalazion, Hordeolum","enrollment":108},{"nctId":"NCT00834171","phase":"","title":"A Retrospective Evaluation of the Intraocular Pressure Spikes With Loteprednol and Loteprednol/Tobramycin","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-01","conditions":"Ocular Hypertension","enrollment":50},{"nctId":"NCT00781300","phase":"PHASE4","title":"Intraocular Pressure With Loteprednol and Dexamethasone","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2006-03","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zylet"],"phase":"marketed","status":"active","brandName":"Loteprednol/tobramycin","genericName":"Loteprednol/tobramycin","companyName":"Massachusetts Eye and Ear Infirmary","companyId":"massachusetts-eye-and-ear-infirmary","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Loteprednol reduces ocular inflammation via glucocorticoid receptor activation, while tobramycin provides broad-spectrum bacterial coverage by inhibiting bacterial protein synthesis. Used for Steroid-responsive inflammatory ocular conditions with bacterial infection or risk thereof, Post-operative ocular inflammation and infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}